Abstract: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions.
Type:
Grant
Filed:
January 26, 2007
Date of Patent:
April 19, 2011
Assignee:
FibroGen, Inc.
Inventors:
Michael Arend, Lee A. Flippin, Min Wu, Eric D. Turtle, Wen-Bin Ho, Shaojiang Deng
Abstract: This invention provides a class of androgen receptor targeting agents. The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM).
Type:
Grant
Filed:
February 16, 2006
Date of Patent:
April 5, 2011
Assignee:
University of Tennessee Research Foundation
Inventors:
James T. Dalton, Duane D. Miller, Yali He, Donghua Yin
Abstract: The invention relates to a process for treating lameness with an osseous, articular or osteoarticular component, comprising the administration, to a human or to an animal not suffering from arthritis or from fractures, of an effective amount of a bisphosphonic acid derivative of formula: in which: R1 represents a hydrogen atom, a halogen atom, a hydroxyl, an amino, a mono(C1-C4)alkylamino or a di(C1-C4) alkylamino; R2 represents a halogen atom, a linear alkyl comprising from 1 to 5 carbon atoms which is unsubstituted or substituted with a group chosen from a chlorine atom, a hydroxyl, an amino, a mono(C1-C4)alkylamino or a di(C1-C4)alkylamino; a (C3-C7) cycloalkylamino, or R2 represents a phenoxy, a phenyl, a thiol, a phenylthio, a chlorophenylthio, a pyridyl, a pyridyl-methyl, a 1-pyridyl-1-hydroxymethyl, an imidazolyl-methyl or a 4-thiomorpholinyl, of one of its pharmaceutically acceptable salts or of one of its hydrates.
Type:
Grant
Filed:
November 28, 2003
Date of Patent:
March 29, 2011
Assignee:
Ceva Sante Animale
Inventors:
Philippe Du Mesnil, Thierry Bardon, Dominique Thibaud
Abstract: The present invention relates to the use of specific derivatives of triazinetriones for controlling coccidioses in livestock, especially pigs.
Abstract: Methods to cause tissue, such as mucosal cells, to express increased amounts of bactericidal permeability increasing protein (BPI) are described. The BPI inducing agents include, for example, lipoxin compounds.
Abstract: An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution.
Type:
Grant
Filed:
February 13, 2009
Date of Patent:
March 29, 2011
Assignee:
Wyeth Holdings Corporation
Inventors:
Jonathan Marc Cohen, Syed Muzafar Shah, Christian Luther Ofslager, Mahdi Bakir Fawzi
Abstract: The present invention provides methods and compositions for modulating levels of amyloid-? peptide (A?) exhibited by cells or tissues. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate A? levels. The invention also provides modulation of A? levels via selective modulation (e.g., inhibition) of ATP-dependent ?-secretase activity. The invention also provides methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an A?-related disorder, by administering a modulator of ?-secretase, including, but not limited to, a selective inhibitor of ATP-dependent ?-secretase activity or an agent that decreases the formation of active (or optimally active) ?-secretase. The invention also provides the use of inhibitors of ATP-dependent ?-secretase activity to prevent, treat or ameliorate the symptoms of Alzheimer's disease.
Type:
Grant
Filed:
January 6, 2003
Date of Patent:
March 22, 2011
Assignee:
The Rockefeller University
Inventors:
William Netzer, Paul Greengard, Huaxi Xu
Abstract: Methods for modulating proteasome activity in a subject is provided. Proteasome activity is modulated by administering a therapeutically effective amount of proteasome modulating pharmacological agent to a subject. In a preferred embodiment, the proteasome modulating pharmacological agent is a protease inhibitor. In another aspect, a screening assay for detecting and identifying proteasome modulating pharmacological agents to modulate proteasome activity in a subject is also provided.
Type:
Grant
Filed:
June 3, 2003
Date of Patent:
March 8, 2011
Assignee:
ALS Therapy Development Foundation, Inc.
Abstract: Stable emulsions comprising as a base one or more diene conjugated fatty acids. Amino acids and other macromolecules can be used to stabilize the emulsion. The emulsion is also useful as a carrier and delivery vehicle of the macromolecules to humans or animals in need of the macromolecules. Plant oil extracts, such as conjugated linoleic acid and its acylated derivatives, are useful as the diene conjugated fatty acids that form the base of the stable emulsion. The emulsions formed are useful as nutritional or cosmetic adjuvant for oral based nutrition, skin diseases, cosmetic utility, enhancing oral nutrition, or pharmacological benefit. Methods of producing and using the emulsions are also provided.
Abstract: The invention provides immunostimulatory compositions comprising a small molecule immuno-poteniator (SMIP) compound and methods of administration thereof. Also provided are methods of administering a SMIP compound in an effective amount to enhance the immune response of a subject to an antigen. Further provided are novel compositions and methods of administering SMIP compounds alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma.
Abstract: Ultrasound contrast agents comprising microbubbles of biocompatible gas, e.g. a sulphur halide or a perfluorocarbon, stabilized by opsonisable amphiphilic material, e.g. a membrane-forming lipid such as a phospholipid, especially a negatively charged phospholipid such as a phosphatidylserine, may exhibit prolonged contrast-generating residence time in the liver following intravenous administration.
Type:
Grant
Filed:
September 13, 2001
Date of Patent:
February 22, 2011
Assignee:
GE Healthcare AS
Inventors:
David Johnson, Jonny Østensen, Morten Eriksen, Audun Tornes, Sigmund Frigstad, Harald Dugstad, Jo Klaveness, Pål Rongved, Roald Skurtveit, Jorunn Brænden
Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
Type:
Grant
Filed:
March 13, 2006
Date of Patent:
February 1, 2011
Assignee:
Wyeth LLC
Inventors:
Mahdi B. Fawzi, Tianmin Zhu, Syed M. Shah
Abstract: Novel guanidine compounds having the formula in which R1, R2 and R4 are as defined, are effective as sodium channel blockers in neuronal mammalian cells and as anesthetics and/or analgesics, particularly local spinal and/or epidural anesthetics, for alleviation of neuropathic pain, for providing a neuroprotective effect, and for producing anti-convulsant effects.
Abstract: The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors.
Type:
Grant
Filed:
October 7, 2005
Date of Patent:
January 11, 2011
Assignee:
Cold Spring Harbor Laboratory
Inventors:
Timothy P. Tully, Filippo Cavalieri, Rusiko Bourtchouladze
Abstract: A stabilised composition having antibacterial, antiviral and/or antifungal activity, said composition comprising silver ions and a ligand, characterised in that the composition comprises a complex of silver and a ligand selected from the group consisting of 5,5-disubstituted hydantoins in which the substituents do not comprise conjugated unsaturated bonds and barbituric acid and derivatives thereof stabilising silver ions against reduction to free silver in a hydrophilic environment, and that the composition has a solubility in water higher than 10 mg Ag/l is stable during sterilisation and retains the activity without giving rise to darkening or discoloration of the dressing during storage.
Abstract: This invention provides: 1) a method of treating a subject suffering from a muscle wasting disorder; 2) a method of preventing a muscle wasting disorder in a subject; 3) a method of treating, preventing, suppressing, inhibiting or reducing muscle loss in a subject suffering from a muscle wasting disorder; 4) a method of treating, preventing, inhibiting, reducing or suppressing muscle wasting in a subject suffering from a muscle wasting disorder; and/or 5) a method of treating, preventing, inhibiting, reducing or suppressing muscle protein catabolism in a subject suffering from a muscle wasting disorder, by administering to the subject a selective androgen receptor modulator (SARM) and/or an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, impurity or crystal of said SARM compound, or any combination thereof.
Type:
Grant
Filed:
September 7, 2005
Date of Patent:
December 21, 2010
Assignee:
University of Tennessee Research Foundation
Inventors:
James T. Dalton, Duane D. Miller, Mitchell S. Steiner, Karen A. Veverka
Abstract: A pharmaceutical composition comprising: (a) a salt of formula 1 wherein: X? is an anion with a single negative charge; and (b) a steroid 2, processes for preparing such pharmaceutical composition, and their use in the treatment of respiratory complaints.
Type:
Grant
Filed:
April 20, 2006
Date of Patent:
December 14, 2010
Assignee:
Boehringer Ingelheim Pharma GmbH & Co. KG
Inventors:
Rolf Banholzer, Helmut Meissner, Gerd Morschhaeuser, Michael P. Pieper, Gerald Pohl, Richard Reichl, Georg Speck, Christopher John Montague Meade, Michel Pairet
Abstract: The present invention generally relates to pharmaceutical compositions comprising ethers of 3-hydroxyphenylacetic acid. The present invention also relates to therapeutic uses of the ethers of 3-hydroxyphenylacetic acid. The ethers of 3-hydroxyphenylacetic acid have the chemical structural of formula (I): where R is an aromatic or arylalkyl substituent.
Type:
Grant
Filed:
February 16, 2007
Date of Patent:
November 23, 2010
Assignees:
University of Maryland, Baltimore, Board of Regents, The University of Texas System
Inventors:
Andrew Coop, Maharaj K. Ticku, Charles P. France
Abstract: A method of inducing ovulation in a female suffering from anovulatory infertility which comprises administering to said female two or more daily doses of at least one aromatase inhibitor. A method for augmenting ovulation in an ovulating female suffering from unexplained infertility or another type of ovulatory infertility which comprises administering to said female two or more daily doses of at least one aromatase inhibitor early in one or more menstrual cycles. A method of substantially reducing dosage levels of follicle stimulating hormone (FSH) for administration to a female undergoing infertility treatment which comprises administering a combination of two or more daily doses of at least one aromatase inhibitor (AI) with a plurality of daily doses of follicle stimulating hormone (FSH).
Type:
Grant
Filed:
April 17, 2001
Date of Patent:
October 26, 2010
Assignee:
Ares Trading S.A.
Inventors:
Robert F. Casper, Mohamed F. M. Mitwally
Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
Type:
Grant
Filed:
October 19, 2004
Date of Patent:
October 5, 2010
Assignee:
Otsuka Pharmaceutical Co., Ltd.
Inventors:
Janusz W. Kostanski, Takakuni Matsuda, Manoj Nerurkar, Vijay H. Naringrekar